These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15934887)

  • 1. Pharmacotherapy of onychomycosis.
    Baran R; Gupta AK; Piérard GE
    Expert Opin Pharmacother; 2005 Apr; 6(4):609-24. PubMed ID: 15934887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK; Gregurek-Novak T
    Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis.
    Bonifaz A; Guzmán A; Garcia C; Sosa J; Saúl A
    Int J Dermatol; 1995 Jul; 34(7):500-3. PubMed ID: 7591419
    [No Abstract]   [Full Text] [Related]  

  • 5. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
    Jaiswal A; Sharma RP; Garg AP
    Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for onychomycosis: a review.
    Gupta AK; Tu LQ
    Dermatol Clin; 2006 Jul; 24(3):375-9. PubMed ID: 16798436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new oral antifungal agents for onychomycosis of the toenails.
    Gupta AK; Shear NH
    J Eur Acad Dermatol Venereol; 1999 Jul; 13(1):1-13. PubMed ID: 10565624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onychomycosis.
    Welsh O; Vera-Cabrera L; Welsh E
    Clin Dermatol; 2010 Mar; 28(2):151-9. PubMed ID: 20347657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment of onychomycosis.
    Thappa DM
    Indian J Dermatol Venereol Leprol; 2007; 73(6):373-6. PubMed ID: 18032853
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis.
    Del Rosso JQ
    J Am Osteopath Assoc; 1997 Jun; 97(6):339-46. PubMed ID: 9232944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for onychomycosis a systematic review and network meta-analysis of mycological cure.
    Gupta AK; Daigle D; Paquet M
    J Am Podiatr Med Assoc; 2015 Jul; 105(4):357-66. PubMed ID: 25032982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
    Gupta AK
    Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antifungal therapies for the treatment of onychomycosis.
    Kumar S; Kimball AB
    Expert Opin Investig Drugs; 2009 Jun; 18(6):727-34. PubMed ID: 19426118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
    Seidl HP; Jäckel A; Müller J; Schaller M; Borelli C; Polak A
    Mycoses; 2015 Oct; 58(10):610-9. PubMed ID: 26334024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open randomized comparison of itraconazole versus terbinafine in onychomycosis.
    Arenas R; Domínguez-Cherit J; Fernández LM
    Int J Dermatol; 1995 Feb; 34(2):138-43. PubMed ID: 7737776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efinaconazole and Tavaborole.
    Poulakos M; Grace Y; Machin JD; Dorval E
    J Pharm Pract; 2017 Apr; 30(2):245-255. PubMed ID: 26873506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical and physical strategies in onychomycosis topical treatment: A review.
    Angelo T; Borgheti-Cardoso LN; Gelfuso GM; Taveira SF; Gratieri T
    Med Mycol; 2017 Jul; 55(5):461-475. PubMed ID: 27703019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.
    Arikian SR; Einarson TR; Kobelt-Nguyen G; Schubert F
    Br J Dermatol; 1994 Apr; 130 Suppl 43():35-44. PubMed ID: 8186141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onychomycosis: pathogenesis, diagnosis, and management.
    Elewski BE
    Clin Microbiol Rev; 1998 Jul; 11(3):415-29. PubMed ID: 9665975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.